Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas Biopharma (MTNB) is a clinical-stage biopharmaceutical innovator leveraging lipid-crystal nanoparticle technology to develop oral anti-infectives for complex diseases. This page aggregates all official news releases and verified updates related to the company’s clinical progress, strategic partnerships, and regulatory milestones.
Investors and industry professionals will find timely updates on clinical trial results, FDA communications, and corporate developments, including advancements in MTNB’s encochleated drug pipeline. The resource prioritizes accuracy and relevance, offering stakeholders a streamlined way to track the company’s work in transforming anti-infective therapies through nanotechnology.
Key content categories include updates on lead candidates like MAT2203 (oral amphotericin B) and MAT2501 (encochleated amikacin), intellectual property announcements, and collaborations addressing orphan infectious diseases. All materials are sourced directly from company filings and authorized communications to ensure reliability.
Bookmark this page for efficient access to MTNB’s latest developments in drug reformulation and nano-encapsulation technology. Check back regularly for critical updates that could inform long-term investment and research strategies in the biopharmaceutical sector.
Matinas BioPharma (NYSE American: MTNB) announced promising in vitro data on their lipid nanocrystal (LNC) platform for delivering small oligonucleotides. Presented at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, the data demonstrated up to 70% gene knockdown in targeted cytokines using murine macrophages. The LNCs encapsulate and protect small oligonucleotides like ASOs and siRNA, showing successful delivery and biological activity even after exposure to gastric fluid. This could make LNCs a promising oral drug delivery platform for various therapeutic applications.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) reported financial results for Q1 2024, with $10 million financing to fund development programs. Discussions continue to partner for Phase 3 trial of oral MAT2203, showing promising results in fungal infections. LNC platform expansion into inflammation and oncology is supported by positive data. Cash position is strong, with $8.1 million as of March 31, 2024, sufficient to fund operations into Q2 2025.
Matinas BioPharma Holdings, Inc. announces that Chief Medical Officer, James J. Ferguson, will present two abstracts at the ASGCT Annual Meeting on the use of its lipid nanocrystal (LNC) platform for small oligonucleotide delivery. The presentations will focus on the uptake and targeted delivery of small oligonucleotides in innate immune cells and the successful in vivo oral delivery of therapeutic anti-inflammatory mRNA-targeted oligonucleotides using the LNC platform.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) will report first quarter 2024 financial results on May 9, 2024. The company, known for its lipid nanocrystal platform technology, will discuss financials and business updates in a webcast. Investors can participate in the conference call or webcast to gain insights into the company's performance.
Matinas BioPharma's oral formulation MAT2203, a less invasive treatment for mucormycosis, shows efficacy in treating fungal infections in mice. The study demonstrates prolonged survival, reduced fungal burden, and improved lung infection.
The promising results suggest that MAT2203 could be a safer alternative to current treatments, with potential benefits in treating various invasive fungal infections.
FAQ
What is the current stock price of Matinas Biopharm (MTNB)?
What is the market cap of Matinas Biopharm (MTNB)?
